Company Profile
Sarepta Therapeutics Stock Price, News & Catalysts
- Ticker:
- SRPT
- Exchange:
- NASDAQ
- Sector:
- Gene Therapy
- Location:
- United States
Stock performance
18.18 USD (+0.44%)
Close
Last updated: August 17, 2026
1.72B USD
Market cap
Why the stock is moving
As of Aug 17, 2026, SRPT closed up 0.44% at $18.18. No new same-company headline was identified in the current news window.
Company overview
Precision Genetic Medicine
Sarepta Therapeutics develops and commercializes genetic medicines for rare neuromuscular diseases, with a major focus on Duchenne muscular dystrophy.
ELEVIDYS
ELEVIDYS is an AAV-based gene-transfer therapy that delivers a micro-dystrophin transgene to skeletal muscle. It is indicated for ambulatory patients aged four years and older with confirmed Duchenne mutations.
Exon-Skipping Franchise
EXONDYS 51, VYONDYS 53 and AMONDYS 45 use phosphorodiamidate morpholino oligomers to skip specific dystrophin exons in genetically eligible Duchenne patients.
siRNA Platform
SRP-1001 and SRP-1003 are integrin-targeted siRNA candidates in Phase 1/2 development for facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1.
Global Commercial Partnerships
Sarepta commercializes directly in the United States and works with Roche and Chugai on ELEVIDYS outside the U.S., combining internal development with regional partnerships.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Sarepta Therapeutics (SRPT)?
Sarepta Therapeutics (SRPT) most recently closed at 18.18 USD, a +0.44% move versus the previous session.
What is the market cap of Sarepta Therapeutics (SRPT)?
Sarepta Therapeutics currently has a market capitalization of 1.72B USD on BioPharmSignal.
What does Sarepta Therapeutics do?
Precision Genetic Medicine Sarepta Therapeutics develops and commercializes genetic medicines for rare neuromuscular diseases, with a major focus on Duchenne muscular dystrophy. ELEVIDYS ELEVIDYS is an AAV-based gene-transfer therapy that delivers a micro-dystrophin transgene to skeletal muscle. It is indicated for ambulatory patients aged four years and...
On which exchange is SRPT stock listed?
Sarepta Therapeutics (SRPT) is associated with NASDAQ, United States, Gene Therapy.
What is SRP-1001?
siRNA Platform SRP-1001 and SRP-1003 are integrin-targeted siRNA candidates in Phase 1/2 development for facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1.
Which conditions is Sarepta Therapeutics targeting with SRP-1001?
Sarepta Therapeutics is associated with genetic disease based on its company overview and current catalyst commentary.
What is SRP-1003?
siRNA Platform SRP-1001 and SRP-1003 are integrin-targeted siRNA candidates in Phase 1/2 development for facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1.
What is Precision?
Precision Genetic Medicine Sarepta Therapeutics develops and commercializes genetic medicines for rare neuromuscular diseases, with a major focus on Duchenne muscular dystrophy.